InnoCure Therapeutics Inc.
- Biotech or pharma, therapeutic R&D
- Other R&D services
- Synthesis, analytic, diagnostic services
InnoCure Therapeutics is a privately held biopharmaceutical company dedicated to the discovery and development of novel drugs based on next-generation target protein degradation (TPD) mechanisms applicable to 'undruggable' targets in cancers and rare diseases.
Our TPD / PROTAC development platform consists of
1) ELCBIL (E3 Ligase CRBN Binder Library) - library of new CRBN binder ligands
2) MOGLUBIN (Molecular Glue Binder) - library of new Molecular Glue binder
3) MILPROTAC - technique to develop oral dose for TPD drugs
4) DAC (Degrader Antibody Conjugate) - safe new modality to improve ADC toxicity & resistance
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}